- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Samsung Biologics and AstraZeneca Dissolve Rituximab Partnership
Their rituximab biosimilar candidate was advancing in clinical trials for equivalence but represented a business conflict.
Samsung Biologics has decided to abandon efforts to develop SAIT101, a rituximab biosimilar for the treatment of follicular lymphoma, according to a report in the Korea Biomedical Review.
The report cited a corporate financial disclosure and official statement this week that stated Samsung Biologics and AstraZeneca had decided to suspend long-running research and development activities by a jointly owned subsidiary, Archigen Biotech, which was solely engaged in development of the rituximab candidate. Samsung Biologics said the subsidiary would be dissolved.
There was a conflict of interest in that a member of the Samsung Group, Samsung Bioepis, was in business collaboration with Biogen, the original developer of Rituxan, the reference brand of rituximab, the report said.
The report estimated that Samsung Biologics had invested $126 million in Archigen Biotech since its founding in 2016. A global phase 3 trial of SAIT101 in patients with follicular lymphoma was completed in August 2020 and demonstrated similar therapeutic effects to the reference product, with an objective response rate of 66.3% vs 70.6% for the Republic of Korea–marketed version of rituximab, MabThera.
Phase 1 trial results of the biosimilar candidate vs MabThera in patients with rheumatoid arthritis demonstrated therapeutic equivalence.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
